Union Budget 2025, to be presented on 1 February, is expected to focus on fuel price cuts, tax relief for the middle class, ...

Viatris has faced volatility since its 2020 formation but is now in Phase 2 of its transformation. Learn why VTRS stock could ...

The Finance Minister is expected to prioritise economic growth, domestic manufacturing, and offer relief to consumers in the upcoming budget to address inflation, fiscal consolidation, and job creatio ...

Syngene reported 18% YoY growth in Q3FY25 net profit. Revenue rose 11% YoY. EBITDA margin improved to 31.4%. Company expects ...

Biocon advanced 2.41% to Rs 397.20 after its board is scheduled to meet on Monday, 27 January 2025, to consider and approve the raising of funds on a private placement basis.

BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2025 ,inter alia, to consider and approve Raising of Funds through issuance of Commercial ...

Biocon stock price is poised for a fresh breakout from its consolidation range of 320-395, following nearly three and a half ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

China's rural healthcare gap impacts timely medical response; the EU plans to ban 'forever chemicals'; North America eases ...

India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major ...

India should eliminate tax on drugs for cancer treatment and chronic diseases, urged Biocon's chairperson Kiran Mazumdar-Shaw ...

Shaw, chairperson of Biocon Ltd, urges the Indian government to eliminate taxes on drugs for cancer and chronic diseases.